newsfilter
← Latest News
PR Newswire·

Aequus and reVision to Collaborate on Stargardt Disease Program

VANCOUVER, BC and RIDGEWOOD, N.J., Aug. 17, 2021 /PRNewswire/ -- Aequus Pharmaceuticals Inc. (TSXV:AQS) (OTCQB:AQSZF) ("Aequus") and reVision Therapeutics, Inc. ("reVision") announce a collaboration on the development of a therapy for Stargardt disease.